Diagnosis of diarrhea-predominant irritable bowel syndrome (IBS-D) relies on the Rome IV symptom-based criteria, which are imperfect for separating functional vs organic disease. Biomarker tests for IBS-D might be added to symptom data to allow clinicians to make more accurate and precise diagnoses in a cost-effective manner. We tested the economic consequences of using a range of hypothetical IBS-D biomarkers, and explored at what cost and level of accuracy a biomarker becomes cost effective. We produced a framework for payers to evaluate the return on an investment of implementing IBS-D biomarkers of varying accuracy and cost.
I rritable bowel syndrome (IBS) is a functional gastrointestinal disorder (FGID) that is characterized by recurrent abdominal pain and altered bowel habits. 1 With an estimated worldwide prevalence of 11%, IBS is the most commonly diagnosed gastrointestinal condition. 2, 3 Moreover, the economic burden of IBS is substantial, with total costs estimated at $30 billion annually in the United States. 4 Current diagnostic criteria for IBS are symptombased, because the Rome IV criteria require recurrent abdominal pain !1 day per week in the last 3 months associated with !2 of the following: (1) related to defecation, (2) change in stool frequency, and (3) change in stool form. 1 However, abdominal pain with altered bowel habits is not exclusive to IBS. Individuals with celiac disease, inflammatory bowel disease (IBD), and microscopic colitis, among other conditions, can present with similar symptoms to those with IBS.
The inability of symptom-based measures to differentiate between those with functional versus organic disease calls for a need to supplement symptom data with objective biomarkers. A clinically useful biomarker measures pathogenic processes specific to IBS, thereby enhancing diagnostic accuracy by distinguishing individuals with IBS from those who are healthy or have organic disease. [5] [6] [7] The Rome IV Multidimensional Clinical Profile also recognizes the evolving utility of biomarkers, because they are part of the multicomponent assessment system along with Rome diagnosis, clinical modifiers, personal impact, and psychosocial influences. 8 IBS biomarkers may even allow clinicians to make more precise diagnoses in a costeffective manner by allowing them to "rule in" IBS and forgo usually fruitless and costly diagnostic testing for organic disease. 9 Because of the high prevalence and large economic burden of IBS, along with the increasing number of existing and emerging diarrhea-predominant irritable bowel syndrome (IBS-D) laboratory biomarkers, all of which will have different profiles of sensitivity, specificity, and cost, it is important to estimate the economic consequences of using these tests. In this study, we tested at what cost and accuracy a biomarker will become cost effective, as well as cost saving, in clinical practice. The result is a quantitative framework, which is supported by lookup tables and economic projection graphs, to guide investigators and payers as they develop, validate, price, and/or reimburse IBS-D biomarkers for use in everyday clinical practice.
Methods

Model Overview
We used decision analysis software (TreeAge Pro 2016; TreeAge Software, Inc, Williamstown, MA) to evaluate a hypothetical cohort of patients who met Rome IV IBS-D criteria. Individuals entered the model without previous intervention and underwent 1 of 2 competing strategies, usual care or an IBS biomarker-based diagnostic approach. We followed the cohort during a 1-year time horizon; all individuals were diagnosed with the correct underlying condition (IBS-D, celiac disease, IBD, or microscopic colitis) within 1 year. Figure 1 displays the truncated decision model. In addition to meeting Rome IV IBS-D criteria, we also assumed patients did not have significant alarm symptoms (eg, severe hematochezia, hematemesis, unintentional weight loss) that warrant expedited endoscopic evaluation. Of note, prior research has found that the diagnostic yield of non-severe alarm features in IBS and other FGIDs is low. [10] [11] [12] [13] Moreover, all individuals entered the model having a normal complete blood count, basic metabolic panel, and negative infectious stool studies. Celiac serologies were not included in the initial evaluation because a meta-analysis revealed that the utility of universally screening for celiac disease in those with suspected IBS in the United States is not clear. 14 
Competing Strategies
Usual care. Because all patients met Rome IV criteria and did not have worrisome features, those in the usual care arm first received empiric IBS-D therapy rather than additional diagnostic testing. Because there is no accepted first-line IBS-D therapy along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for a low fermentable oligo-, di-, mono-saccharides, and polyols (FODMAP) diet trial, and the remainder received antidiarrheals/anti-spasmodics. Those who did not respond to first-line therapy then received a 2-week course of rifaximin. Because there are many other variations in how IBS-D patients are managed by different providers, we varied these assumptions in subsequent sensitivity analyses via Monte Carlo simulations, which we describe below. Sensitivity analysis allows the model to incorporate a wide range of projected clinical benefits to simulate natural proactive variations in IBS-D management.
Individuals who did not respond to the first 2 lines of treatment underwent diagnostic testing with celiac serologies, C-reactive protein (CRP), and endoscopy with mucosal biopsies (esophagogastroduodenoscopy for those with positive celiac antibodies and colonoscopy for those with negative antibodies) to screen for organic disease, as suggested by Rome IV for evaluation of persistently symptomatic patients. 1 Other work-up such as liver and thyroid tests, lactase gene test, calcium, etc were not included because of findings by Begtrup et al 15 that limited testing was non-inferior and less costly versus a strategy of exclusion. Those found to have organic disease were treated accordingly, whereas patients with unrevealing tests received a third-line IBS-D therapy (modeled using eluxadoline).
Response rates for each line of therapy depended on the underlying condition. For those truly with IBS-D (ie, no organic disease), the model reflected the traditional "adequate relief" response rates from IBS clinical trials, a validated and widely used endpoint in the published literature. 16 All patients were seen by a gastroenterologist 1 month after initiation of therapy to determine whether they responded to the treatment. Finally, the model assumed that IBS-D patients who responded to a therapy remained in adequate relief during their remaining time in the model.
For those with true organic disease, our model accounted for a placebo effect from empiric IBS-D therapies; this value was modeled as the placebo response rate seen in IBS trials. 17 We assumed that those who responded to an IBS-D therapy had symptom relief for 1 month. During the second month of treatment, patients became symptomatic again because their underlying disease was not being treated by the IBS therapy, requiring another gastroenterologist visit for further evaluation and management.
Irritable bowel syndrome biomarker-based diagnostic strategy. In the biomarker-based arm, individuals were first tested with a hypothetical IBS-D biomarker. Those with a positive test received up to 3 failed IBS-D treatments, as compared with 2 courses in usual care, before undergoing diagnostic testing to screen for organic disease. The model allowed for 3 treatment trials because the purpose of targeted biomarkers is to rule in IBS-D with a positive test, thus reducing the need for additional exclusionary testing. Nonetheless, the model assumes that pragmatic clinicians will still question a positive IBS-D test if a patient has ongoing symptoms despite treatment and will return to exclusionary testing in the face of repeated treatment failures. Thus, the model is designed to reflect judicious clinical practice and not bias the model in favor of the biomarker-based strategy.
Patients with a positive biomarker test who subsequently required and had negative diagnostic testing remained with an IBS-D diagnosis (ie, true positive), whereas those with an alternative diagnosis identified through exclusionary testing were managed for the corresponding disease (ie, false positive). Conversely, a negative biomarker test prompted upfront diagnostic testing, which dictated subsequent management. Individuals whose testing revealed organic disease (ie, true negative) were treated accordingly. Those with negative diagnostic testing (ie, false negative) were diagnosed with IBS and received up to 3 IBS-D treatments. Thus, the model penalizes false-negative biomarker tests by incorrectly assuming the patient did not have IBS and triggering more testing for organic disease.
Clinical Probability Estimates
Our base-case model incorporated a wide range of estimates governing relevant clinical probabilities in the evaluation and management of Rome IV IBS-D positive patients (Table 1) . To derive these estimates, we retrieved pertinent studies in MEDLINE and used a weighted average of estimates when multiple studies were identified.
Outcomes: Cost-Utility Approach
By using a cost-utility approach, we used cost per quality-adjusted life years (QALYs) as our main outcome and reported the incremental cost per QALY gained between the 2 competing strategies. We used a willingnessto-pay (WTP) threshold of $100,000/QALY gained because health economists have determined that the traditionally used $50,000/QALY benchmark is too low for the United States. 18 Utility estimates. The model included relevant health state utilities for those with untreated and treated IBS-D, celiac disease, IBD, and microscopic colitis. We searched Figure 1 . Truncated decision model. Individuals in the usual care arm first received empiric IBS-D therapy and needed to fail 2 treatment courses before undergoing additional diagnostic testing with endoscopy, celiac serologies, and CRP. Those in the IBS-D biomarker-based approach first had a biomarker test. Individuals with a positive test received IBS-D therapy, and diagnostic testing was only performed after 3 failed treatment courses. On the other hand, those with a negative biomarker test had immediate diagnostic testing, which determined whether the patient was treated for organic disease (celiac disease, IBD, or microscopic colitis) or IBS-D. ,, decision node; , probability node; 9, terminal node.
the Tufts Cost-Effectiveness Analysis Registry to identify pertinent utilities (Table 1) . 19, 20 All patients entered the model without significant alarm features, so those with untreated celiac disease, IBD, and microscopic colitis were assumed to have the same utility as those with untreated IBS-D. The overall QALY calculated for each individual accounted for the amount of time spent in each state (ie, untreated or treated). Because our study cohort was followed for a 1-year period, discounting was not performed.
Cost estimates. Our model accounted for total costs incurred from a third-party payer perspective. Table 2 depicts the base-case cost estimates, and eAppendix 1 describes these estimates in detail. We obtained costs for procedures and physician services by using the 2017 American Medical Association Current Procedural Terminology Codebook and the 2017 Centers for Medicare & Medicaid Services (CMS) Physician Fee Schedule. We incorporated the costs associated with lab testing by using the 2017 CMS Clinical Laboratory Fee Schedule. Medication costs were obtained from UpToDate (Wolters Kluwer Health, Alphen aan den Rijn, Netherlands), which provides average wholesale U.S. dollar prices. Discounting was not performed because the time horizon was only 1 year.
Probabilistic sensitivity analyses. We conducted Monte Carlo probabilistic sensitivity analyses and assumed that all variables followed a triangular distribution, with base-case, minimum, and maximum values listed in Tables 1 and 2 . These analyses were carried out across varying biomarker costs and accuracies, and 1000 second-order parameter samples were done for each cost and accuracy combination. Results from the Monte Carlo simulations were used to generate costeffectiveness acceptability curve plots. Because there are many sensitivity and specificity combinations that lead to the same calculated accuracy, we opted to test scenarios where the biomarker's sensitivity, specificity, and thereby accuracy were equal (ie, a test that is 70% sensitive and 70% specific is also 70% accurate).
Outcome: Budget Impact Model Approach
Because the average effectiveness was similar between groups, we also performed a budget impact analysis. Per-member per-month (PMPM) cost served as the outcome, and we calculated the incremental PMPM cost of adopting the IBS biomarker-based approach versus usual care in a hypothetical managed care organization (MCO) with 1,000,000 covered lives. To perform these calculations, we used a baseline annual incidence of Rome IV IBS-D positivity of 667 per 100,000 patients (assumes overall IBS incidence of 2000 per 100,000, with one-third having diarrhea-predominant symptoms). 21, 22 We calculated the average PMPM cost for each strategy across a range of biomarker costs and accuracies by multiplying the average monthly cost per patient with Rome IV positivity by the total number of patients with Rome IV positivity in the hypothetical MCO and then dividing this value by the total number of paying members. To calculate the incremental PMPM between strategies, we used the following expression:
We also conducted sensitivity analyses by varying the Rome IV IBS-D annual incidence from 250 to 2000 per 100,000 individuals.
Results
Cost-Utility Analyses
Base-case results. Figure 2 and Supplementary  Figures 1-7 present nomograms depicting the most cost-effective strategy across varying IBS-D biomarker costs, sensitivities, and specificities. We found that when using a WTP threshold of $100,000/QALY, biomarkers are not cost effective when their price exceeds $846, even when they are 100% accurate.
Probabilistic sensitivity analyses. Figure 3 depicts results from the probabilistic sensitivity analyses with 1000 Monte Carlo simulations across several biomarker cost and accuracy combinations. With a WTP of $100,000/QALY, the large majority of trials (75% or more) favor the biomarker arm above the following price and accuracy thresholds: $100 biomarker, 51% accurate; $200, 57%; $300, 63%; $400, 69%; $500, 76%; $600, 82%; $700, 89%; and $800, 94%. At $900, most trials show that usual care is more cost effective across the tested biomarker accuracies. 
Budget Impact Analyses
In the base case, the average annual cost for an individual in the usual care arm is $3159. Assuming a hypothetical MCO with 1,000,000 covered lives and a Rome IV IBS-D positivity annual incidence of 667 per 100,000 patients, the average PMPM cost for usual care is $1.76. Table 3 shows the incremental PMPM cost of the biomarker-based arm versus usual care stratified by biomarker prices and accuracies. For example, an MCO saves money when it uses a $100 biomarker that is !75% accurate at detecting IBS-D. Conversely, a $300 biomarker needs to be 100% accurate to save $0.02 PMPM. Above $344, regardless of the biomarker's diagnostic properties, its use no longer results in cost savings, and there is an increased PMPM cost.
Supplementary Tables 1-8 show the incremental PMPM costs across several Rome IV IBS-D incidences. For instance, if an MCO has a Rome IV IBS-D incidence of 250 per 100,000 patients and uses a $100 biomarker that is 80% accurate, the organization will save $0.02 PMPM. Conversely, if the same biomarker is used at an MCO where 2000 of every 100,000 meet criteria for Rome IV IBS-D, it will save $0.13 on each member per month.
Discussion
In light of recently approved and emerging objective IBS-D biomarkers in development, [5] [6] [7] we tested the economic consequences of using a wide range of hypothetical biomarker tests with varying diagnostic properties and cost profiles. This study details the accuracy and cost combinations that are required for IBS-D biomarkers to be cost effective and cost saving in clinical practice. These data can serve as "economic blueprints" for guiding investigators and payers as they develop, validate, price, and/or reimburse IBS-D biomarker tests.
We generated detailed lookup tables and projection graphs against which to check the projected cost effectiveness of hypothetical biomarker tests across a range of accuracies and prices by using the increasingly accepted $100,000/QALY WTP threshold. 18 As expected, increasing biomarker costs required improved accuracy at detecting IBS-D for it to remain cost effective. However, when a biomarker test is >$846, it no longer is cost effective compared with usual care, even when 100% accurate.
Because the overall effectiveness between arms was similar, we also performed our analyses from the budget impact perspective. With the increasing number of MCOs and companies with self-insured group health plans, it is important to distinguish cost effectiveness from budget impact. In contrast to cost-effectiveness analysis, which measures both cost and clinical utilities without considering the underlying disease prevalence, budget impact models focus exclusively on cost and consider the prevalence of disease. In our base case, we found that biomarker tests $344 are potentially cost saving as long as they are accurate at detecting IBS-D. When they cost more than $344, using IBS-D biomarkers levies an increased PMPM cost, ranging from $0.01 to $0.53. Still, this value is lower compared with incremental PMPM costs for other common interventions in Figure  2 . Nomogram depicting the preferred strategy when the IBS-D biomarker costs $100 and at a WTP threshold of $100,000/QALY gained. For example, a biomarker that is 80% sensitive and 40% specific is not cost effective versus usual care. However, when increasing the specificity of the same biomarker to 50%, its use becomes cost effective. At varying biomarker costs and accuracies, we performed probabilistic sensitivity analyses using 1000 trials and determined the proportion of trials within the $100,000/QALY WTP threshold. For example, if a $300 biomarker is 60% accurate, then 54.8% of trials would fall within the budget. Conversely, when increasing the accuracy to 75%, 99.6% of trials found that it is cost effective versus usual care. Note: tested scenarios included those where the biomarker's sensitivity, specificity, and thereby accuracy were equal.
gastroenterology/hepatology: (1) $2.86 for intravenous versus oral proton pump inhibitor after high-risk peptic ulcer hemorrhage 23 and (2) $3.40 for rifaximin versus lactulose for hepatic encephalopathy. 24 For IBS-D biomarkers that are not cost saving but remain cost effective versus usual care (ie, incremental cost/QALY <$100,000), MCO executives will need to balance the additional PMPM costs with the QALY benefits gained by its members when considering whether to implement the biomarker test in practice.
This analysis has several strengths. First, our study reports both the cost effectiveness and budgetary impact of hypothetical IBS-D biomarker tests across varying diagnostic and cost profiles. As a result, we developed detailed lookup tables against which to check the projected cost effectiveness of existing and evolving biomarkers for IBS-D. These data are relevant and actionable for investigators developing, validating, and ultimately pricing biomarkers for use in everyday clinical practice. They are also valuable for executives in MCOs and companies with self-insured group health plans, because we recast the clinical data in an economic form that may assist in determining whether to introduce IBS biomarkers into health systems. Second, our model reflects the everyday challenges in the evaluation and management of those with Rome IV IBS-D positivity. It addresses the possibility that those who meet Rome IV IBS-D criteria may have an underlying organic disease. The model also accounts for a placebo effect among those with organic disease receiving IBS therapies. By accounting for these practical issues, our analysis is more likely to reflect the health economic consequences of everyday practice.
There are limitations to our analysis. First, no 2 MCOs are the same, so our base-case budget impact results cannot apply across the wide spectrum of healthcare settings. However, we addressed this limitation by calculating incremental PMPM costs across a broad range of incidences for Rome IV IBS-D positivity.
Second, no 2 clinicians are the same; clinicians often approach IBS-D management with their own styles and strategies. This can make any IBS decision analysis difficult to model but is not a reason to dismiss these models altogether. Instead, the model must account for natural variations in practice, which we accomplish here through multivariable sensitivity analysis in Monte Carlo modeling, allowing for 1000 different clinical scenarios, treatment effect estimates, and patients. Third, the response rates to treatments were modeled as independent and not contingent on prior therapies; this was done because of a lack of relevant studies to inform base-case estimates of conditional treatment response rates. It is unclear whether this differentially impacts the arms, because the model was largely driven by the performance of the biomarker test. Fourth, our findings may not be generalizable to sites outside of the United States because our model included a low celiac disease prevalence (<1%) and U.S. healthcare costs. Fifth, it was beyond the scope of this current study to account for societal costs associated with untreated IBS and organic diseases. Inclusion of indirect costs such as loss in work productivity, transportation expenses, and caregiver costs, among many other factors, may amplify the cost savings related to biomarkers, provided they are accurate at detecting IBS-D. Finally, although not necessarily a methodologic limitation, the study did not account for the heterogeneous etiologies of IBS. 5 A biomarker targeting only one disease mechanism will likely be suboptimal for use in clinical practice. However, our results can be extrapolated to determine the accuracy and cost thresholds required for a multicomponent biomarker panel to become either cost effective or cost saving.
In conclusion, our analyses determined the combinations of price, sensitivity, and specificity required for IBS-D biomarker tests to become cost effective as well as cost saving. Investigators, industry, and MCO healthcare executives can use these data to guide them as they develop, validate, price, and ultimately decide whether to use biomarkers in everyday clinical practice.
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Supplementary Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. b Includes costs for prescriptions and inpatient, outpatient, emergency room, office, and home health services. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. b Includes costs for prescriptions and inpatient, outpatient, emergency room, office, and home health services. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. b Includes costs for prescriptions and inpatient, outpatient, emergency room, office, and home health services. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. b Includes costs for prescriptions and inpatient, outpatient, emergency room, office, and home health services. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit.
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Clinical Gastroenterology and Hepatology Vol. 16, No. 9 Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. b Includes costs for prescriptions and inpatient, outpatient, emergency room, office, and home health services. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. b Includes costs for prescriptions and inpatient, outpatient, emergency room, office, and home health services. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. b Includes costs for prescriptions and inpatient, outpatient, emergency room, office, and home health services. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. b Includes costs for prescriptions and inpatient, outpatient, emergency room, office, and home health services. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. b Includes costs for prescriptions and inpatient, outpatient, emergency room, office, and home health services. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. b Includes costs for prescriptions and inpatient, outpatient, emergency room, office, and home health services. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. b Includes costs for prescriptions and inpatient, outpatient, emergency room, office, and home health services. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. b Includes costs for prescriptions and inpatient, outpatient, emergency room, office, and home health services.
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Clinical Gastroenterology and Hepatology Vol. 16, No. 9 Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit.
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Clinical Gastroenterology and Hepatology Vol. 16, No. 9 Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for diarrhea-predominant irritable bowel syndrome along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietitian for low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received antidiarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, monthly cost associated with a dietitian was assumed to be the average between an initial visit and a follow-up visit. Because there is no accepted first-line therapy for IBS-D along with the fact that there are variations in IBS severity at presentation, we emulated a community-based case-mix by assuming that one-third of patients received tricyclic antidepressant therapy, one-third consulted with a dietician for a low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet trial, and the remainder received anti-diarrheals/anti-spasmodics (modeled as loperamide and hyoscyamine). Moreover, the monthly cost associated with a dietician was assumed to be the average between an initial visit and a followup visit. 
